IND regs offer more ways to expand access - and to charge patients for it
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs. A companion reg also gives companies more options for changing patients for experimental products - if they are willing to open their books up to FDA (1"The Pink Sheet," Aug. 17, 2009)
You may also be interested in...
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs
MDR Is The ‘Mother Of European Industry’s Problems’ − Germany's BVMed At Medica 2023
Higher logistics and energy costs are putting medtech P&Ls under pressure, and compliance with the EU MDR is draining any remaining surplus. Sustainability compliance is another cost to factor in, says BVMed chief executive Marc-Pierre Möll in part 2 of his interview with Medtech Insight at Medica 2023.
Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.